Therefore, a comprehensive assessment of HF risk across the spectrum of dysglycemia stratified by age, sex, and race can help understand potential disparities and inform effective implementation of HF prevention strategies such as aggressive risk factor modification and use of sodium-glucose transporter 2 (SGLT2) inhibitors [22]. The gene discussed is SLC5A2; the disease is hydrops fetalis.